Tesamorelin: FDA-Approved for Visceral Fat

What is tesamorelin?

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), a naturally occurring signaling molecule. It is given by subcutaneous injection and is best known under the brand name Egrifta. It is approved to reduce excess visceral (deep abdominal) fat in adults living with HIV who have lipodystrophy, a condition in which fat accumulates abnormally around the organs.

That approval rests on a substantial body of human research, and the same mechanism has prompted researchers to study tesamorelin in other settings. Those trials measured visceral fat, liver fat and fibrosis, muscle and physical function, and cognition.

How it works

Unlike taking growth hormone directly, tesamorelin acts further upstream. As a GHRH analog, it binds to receptors in the pituitary gland and prompts the body to release its own growth hormone in a more natural, pulsatile pattern. The downstream effects on fat tissue follow from this restored growth-hormone signaling, and the FDA prescribing information describes the same binding-and-release mechanism.

This indirect mechanism is part of why researchers have focused on tesamorelin for visceral fat specifically. Deep abdominal and liver fat are metabolically active and associated with broader health risk, and the trials below were designed around measuring those depots directly rather than overall weight. Because the drug raises growth hormone and its downstream signal IGF-1, trials also track blood sugar and IGF-1 as part of routine safety monitoring.

The trial evidence, from visceral fat to liver and brain

The approval rests on a large, multicenter phase 3 program. The pivotal trial randomized 412 adults with HIV and excess abdominal fat to tesamorelin (2 mg daily) or placebo, with visceral adipose tissue as the primary measure. A study that large and rigorous is what anchored the FDA approval, and it set up everything that came after.

Smaller mechanistic trials then quantified the effect on each fat depot. A 2014 randomized controlled trial published in JAMA studied 48 people with HIV and abdominal fat accumulation and reported a net reduction in visceral adipose tissue of about 42 cm2 versus placebo, along with a reduction in liver fat. It pinned down the effect on the deep-fat depots directly.

A 2019 randomized, multicentre trial in The Lancet HIV looked more closely at non-alcoholic fatty liver disease (NAFLD) in people with HIV. Over 12 months it reduced liver fat by roughly 37% relative to baseline, brought 35% of treated participants below the 5% liver-fat threshold versus 4% on placebo, and limited progression of liver fibrosis. This is solid randomized evidence, within a defined HIV-affected population.

A 2025 phase 2 trial in The Journal of Infectious Diseases explored tesamorelin for neurocognitive impairment in people with HIV and abdominal obesity. It reduced waist circumference but did not show a clear cognitive benefit between groups. Phase 2 trials are earlier-stage and exploratory, designed to probe a signal rather than confirm benefit. Here the fat-reduction effect held while the cognitive question did not resolve.

Research is also moving toward muscle and physical function. A recruiting phase 2 trial run by Massachusetts General Hospital and the University of Colorado is testing tesamorelin combined with exercise in older adults with HIV, measuring strength, lean tissue, and physical performance over 24 weeks. It is enrolling now, so there are no results yet.

Where tesamorelin fits, and who it may suit

The clearest, established use of tesamorelin is reducing excess visceral fat in HIV-associated lipodystrophy. Beyond that, the recurring research themes are liver fat and fibrosis, muscle and physical function, and, more tentatively, cognition. Nearly all of this work has been done within HIV populations, so the strongest claims belong there, and the liver and muscle findings have not yet been tested outside HIV cohorts.

Whether tesamorelin is appropriate for a given person depends heavily on their individual medical picture, including blood sugar and the growth-hormone axis, and that is a judgment a licensed physician makes after proper assessment.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Tesamorelin is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.